ATI 9242

Drug Profile

ATI 9242

Alternative Names: ATI-9242

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ARYx Therapeutics
  • Developer ARYx Therapeutics; Braeburn Pharmaceuticals
  • Class Antipsychotics
  • Mechanism of Action Acetylcholine stimulants; Dopamine release stimulants; GABA modulators; NMDA receptor modulators; Serotonin-7 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 08 Nov 2016 Braeburn Pharmaceuticals completes a phase I trial in Schizophrenia (In volunteers) in USA (NCT02824666)
  • 11 Jul 2016 No development reported - Phase-I for Schizophrenia (In volunteers) in USA (PO)
  • 01 Jun 2016 Phase-I clinical trials in Schizophrenia (In volunteers) in USA (IV) (NCT02824666)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top